key: cord-0327398-6li4u2a5 authors: Mirchandani, Ananda S.; Jenkins, Stephen J.; Bain, Calum C.; Lawson, Hannah; Coelho, Patricia; Murphy, Fiona; Griffith, David; Zhang, Ailiang; Sanchez-Garcia, Manuel A.; Reyes, Leila; Morrison, Tyler; Arienti, Simone; Sadiku, Pranvera; Watts, Emily R.; Dickinson, Rebecca. S.; Clark, Sarah; Ly, Tony; Lewis, David; Kelly, Van; Spanos, Christos; Musgrave, Kathryn M.; Delaney, Liam; Harper, Isla; Scott, Jonathan; Parkinson, Nicholas J.; Rostron, Anthony J.; Baillie, Kenneth J; Clohisey, Sara; Pridans, Clare; Campana, Lara; Starkey-Lewis, Philip; Simpson, A John; Dockrell, David; Schwarze, Jurgen; Hirani, Nikhil; Ratcliffe, Peter J.; Pugh, Christopher W.; Kranc, Kamil; Forbes, Stuart J.; Whyte, Moira K.; Walmsley, Sarah R. title: Hypoxia shapes the immune landscape in lung injury promoting inflammation persistence date: 2022-03-11 journal: bioRxiv DOI: 10.1101/2022.03.11.483935 sha: 5055b7a9adeeecc16cf767246d036b96f27cd0cb doc_id: 327398 cord_uid: 6li4u2a5 Acute Respiratory Distress Syndrome (ARDS), an often-fatal complication of pulmonary or systemic inflammation, has no cure. Hypoxemia is a defining feature, yet its impact on inflammation is often neglected. Patients with ARDS are monocytopenic early in the onset of the disease. Endotoxin or Streptococcus pneumoniae acute lung injury (ALI) in the context of hypoxia replicates this finding, through hypoxia-driven suppression of type I interferon signalling. This results in failed lung monocyte-derived interstitial macrophages (IM) niche expansion and unchecked neutrophilic inflammation. Administration of colony stimulating factor 1 (CSF1) rescues the monocytopenia, alters the circulating classical monocyte phenotype in hypoxic endotoxin-driven ALI and enables lung IM population expansion, thus limiting lung injury in endotoxin- and virally-induced hypoxic ALI. Hypoxia directly alters immune dynamics to the detriment of the host and manipulation of this aberrant response offers new therapeutic strategies for ARDS. directly alters immune dynamics to the detriment of the host and manipulation of this aberrant response offers new therapeutic strategies for ARDS. Acute Respiratory Distress Syndrome (ARDS) is a complication of either pulmonary or extra-pulmonary inflammation and carries a mortality rate of up to 40% 1 . It is defined by lung infiltrates denoting lung inflammation, and systemic hypoxia, commonly requiring mechanical ventilation 1 . Despite decades of research, effective therapies remain elusive 5 and supportive measures are the mainstay treatment 2 . Much of the work investigating possible therapeutic avenues has focused on modulating the inflammatory injury since its persistence is a poor prognostic indicator 3, 4 , however the effects of systemic hypoxia per se on inflammation persistence in ARDS have not been fully explored. Macrophages have been shown to be key to driving inflammation resolution. Lung macrophages can be 10 subdivided by their surface markers into alveolar macrophages (AM) and interstitial macrophages (IM), which inhabit distinct anatomical niches. Under homeostatic conditions, AM self-renew 5, 6, 7 whilst IM require recruitment of circulating monocytes 8, 9 . Interestingly, evidence is emerging for the key role of IM in inflammation regulation 10, 11 and repair 12 . 15 We sought to determine whether systemic hypoxia, as seen in ARDS, including severe COVID-19 disease, affected the lung monocyte-phagocyte system (MPS) and if this in turn impacted on inflammation resolution. We found ventilated ARDS patients were profoundly monocytopenic early in the disease, a phenomenon we replicated in mouse models of hypoxic acute lung injury (ALI). We further demonstrated that hypoxia 20 fundamentally altered both monocyte phenotypes and MPS dynamics during ALI, leading to inflammation persistence, through suppression of type 1 interferon (IFN) signalling pathways. Critically, targeting this pathway with colony stimulating factor (CSF)1 corrected these hypoxia-mediated changes, driving accelerated inflammation resolution. To determine whether hypoxia is associated with alterations in the blood monocyte 5 compartment, we obtained blood from ventilated ARDS patients early (<48 hours from diagnosis and soon after onset of hypoxic insult requiring ventilatory support) or late (>48 hours from diagnosis) and compared it to healthy controls (Table S1) in ARDS monocytes. Also downregulated were genes associated with monocyte adhesion and extravasation (SELL) 14 , trans-endothelial migration (CD99) 15 and LPS signaling responses (MAP2K4) 16 and MAP3K14 17 . Proteomic survey of the sorted classical monocytes from healthy controls and patients with ARDS further revealed a 5 phenotypic switch, with a significant increase in the abundance of secretory granule content within the monocytes in ARDS (Figure 1k, l) . This was observed across all ARDS samples, including patients with SARS-Cov2-associated ARDS, and was associated with altered expression of known hypoxia regulated proteins including SLC2A3 18 , IGFR2 19 , PSMD4 20 and FTL 21 . Taken together these data demonstrate that ARDS affects both 10 the number and nature of monocytes. With systemic hypoxia a defining feature of ARDS, we sought to determine whether the alterations in circulating monocyte profiles in the ARDS patient cohort were consequent upon the presence of hypoxemia. Combining a model of LPS-induced ALI with reduced 15 inspired oxygen levels (Figure 2a ), allowed us to replicate the severe hypoxia and inflammatory insults that define ARDS ( Figure S2a) . Mice tolerated this level of hypoxia well since mice have an oxygen dissociation curve which is shifted to the right, compared to humans, allowing for improved tissue oxygenation at lower oxygen concentrations 22 . The increase in circulating leukocyte counts observed following LPS challenge ( Figure 20 2b) was abolished in hypoxic mice, with an associated reduction in circulating monocytes increased Il1b transcript, a cytokine that has been associated with poorer outcomes in ARDS 24 . Thus, in a mouse model of ALI, hypoxia drives alterations in monocyte number 10 and phenotype that parallel those described in samples from patients with ARDS. Given the effects of hypoxia on circulating monocyte populations, we next explored the consequence of exposure to systemic hypoxia on the immune compartment of the lung. 15 As expected, LPS significantly increased neutrophil numbers in the lung (Figure 3a ) in both hypoxia and normoxia. However, whilst LPS administration also led to a significant expansion of the macrophage (CD45 + Lineage -CD64 bright ) compartment in normoxia, this was completely abolished in the setting of hypoxia (Figure 3b and 3c) . To identify which populations accounted for this hypoxic reduction in total macrophage counts, we further To complement our LPS ALI model, we examined the effects of hypoxia on monocyte/macrophage dynamics using a model of severe streptococcal pneumonia. Mice were inoculated with 10 7 colony forming units of D39 Streptococcus pneumoniae and placed in either hypoxia or normoxia following a period of recovery from the anesthetic. In keeping with the results obtained in the blood in LPS-induced ALI, we saw 10 similar changes in the blood of these mice ( Figure S3a and S3b). Neutrophil recruitment was unimpaired by hypoxic conditions (Figure 3j ). However, hypoxia suppressed expansion of the IM (SiglecF -CD64 + ) population in response to Streptococcus pneumoniae (Figure 3k ), again with a particular loss of the Ly6C + IM compartment ( Figure 3l and 3m). Taken together, these data confirm that hypoxia markedly affects the MPS 15 compartment in the lung irrespective of the nature of the inflammatory stimulus. To determine the mechanism by which hypoxia regulates circulating monocyte numbers, we measured the rate of monocyte output from bone marrow (BM) using bromodeoxyuridine (BrdU). Mice were pulsed with BrdU 12 hours after LPS nebulisation 20 ( Figure 4a ) and the frequency of BrdU + classical monocytes was determined 12 hours later (Figure 4b and 4c ). Given that monocytes do not proliferate in circulation, any BrdU + monocyte in blood must represent a recent emigrant from the BM over the preceding 12 hours 13, 25 Consistent with our phenotypic analysis above, we found that hypoxia, irrespective of the inflammatory stimulus, caused a marked reduction in the proportion of BrdU + blood monocytes (Figure 4b and 4c ). Importantly, this was a selective effect on monocytes since this difference was not seen in lymphocytes ( Figure S4a ) and the LPS equally reduced the proportion of BrdU + circulating neutrophils in hypoxic and normoxic 5 mice ( Figure S4b ). This led us to question whether hypoxia was directly affecting BM hematopoiesis. Examination of the stem cell compartment (Figure 4d Erythropoiesis in hypoxia is a highly regulated adaptive process, aimed at maintaining oxygen delivery in vivo. Both erythrocytes and monocytes originate from the common myeloid progenitor (CMP) 26 (Figure 4i and Figure S4c ) leading us to question whether hypoxia also skewed hematopoiesis in favour of red blood cell production. To this end, 15 we measured the effect of hypoxia on the CMP progeny 26 Given that the effects of increased erythropoiesis are only measurable in the circulation after a few days, it was not surprising that the hematocrit was equivalent between the LPS-treated groups at 24 hours ( Figure S4d ), however we found an elevated hematocrit in hypoxic mice at day 5 post-LPS ( Figure S4e ). Furthermore, unbiased UMAP analysis and summary data of the CD41 -CD32/16cells of LPS-treated mice at day 5 post-ALI demonstrated skewing in the CMP compartment within the bone-marrow was complete 5 at that later timepoint (Figure 4n-p) . Human data from severely hypoxic patients with SARS-Cov2 infection has demonstrated that type I interferon responses are aberrantly blunted early in the disease 27 and this 10 pathway has previously been shown to be key in regulating emergency myelopoiesis, as well as regulating erythropoiesis 28, 29, 30 . We therefore questioned whether hypoxia could directly regulate type 1 interferon signalling responses within the bone marrow compartment. Culture of bone marrow cells from naïve mice in hypoxia (1% FiO2) resulted in a significant blunting of type 1 IFN which in patients with ARDS has been shown to be persistently higher in non-survivors 24 . Moreover, mice housed in hypoxia had an exaggerated weight loss profile following LPS challenge compared to their normoxic counterparts, with failure to recover to baseline by day 5 (Figure 6k ). Collectively, these data demonstrate that hypoxia-induced monocytopenia is associated with persistent lung inflammation with systemic consequences that are detrimental to the host. To extend our in vivo observations to a model of ARDS driven by virally-induced epithelial injury, mice were challenged with Influenza A in the context of hypoxia ( Figure S5c ). In keeping with our observations in sterile lung injury models, CSF1-Fc treatment increased the number of monocytes recruited into the lung in hypoxic PR8-infected mice ( Figure S5d ), improving physiological outcomes ( Figure S5e ). This was associated with significant reductions in markers of lung injury ( Figure S5f ) and cellular damage (lactate dehydrogenase activity) ( Figure S5g ). In order to dissect the mechanism whereby CSF1-Fc accelerated inflammation resolution, Taken together, these results underpin the importance of monocyte recruitment into the lung during hypoxic lung inflammation in order to drive resolution, as well as the therapeutic potential of CSF1 as a treatment in non-resolving ARDS Hypoxia and alveolar inflammation are the two defining features of ARDS and inflammation persistence in ARDS is a well-known poor prognostic feature 35, 36 We have previously demonstrated how hypoxia negatively affects the host's capacity overcome bacterial ALI 37 and this study expands on those findings to define the impact of hypoxia 5 on the host's capacity to drive inflammation resolution. Monocytes are professional phagocytes 38 , and as such, are key mediators of restoration of homeostasis 39 . We show that, despite the heterogeneity in the aetiology of disease, patients with early ARDS, including those infected with SARS-CoV-2, are monocytopenic and display a defective functional profile with markedly reduced HLADR expression and In the context of prioritising the preservation of tissue oxygen-delivery, the skewing towards erythropoiesis makes physiological sense, for example in adaptation to altitude 40 where monocytopenia has been observed as early as 1969 41 . However, when 20 engagement of an effective innate immune response is also required, our data would suggest that these hypoxia-induced changes have consequences for inflammation resolution with persistence of neutrophilic inflammation. This is clinically important as evidenced most recently by the current COVID-19 pandemic, in which disordered innate and adaptive host responses co-exist with severe systemic hypoxia 42, 43 . Monocytes appear to be highly plastic and their phenotype has been shown to be determined before their release into the bloodstream. Yanez et al demonstrated that the monocyte phenotype generated in the bone marrow is dependent on the nature of the 5 insult driving the emergency myelopoiesis, hence a TLR4 ligand drives "neutrophil"-like monocyte production, whereas a TLR9 ligand generates a more "DC"-like cell 44 . This balance, however is in the context of normoxia. Interestingly, the presence of a "bacterial" signature, with suppressed type I IFN responses has been shown in patients severely unwell with influenza 45 whilst ifnar-/-monocytes have increased expression of granule-10 associated genes 46 . Importantly, data from our ARDS patients demonstrate that this "bacterial" phenotype was present in both bacterialand viral-induced ARDS. Furthermore, our in vivo data show that hypoxia per se, inhibits type I interferon responses in the bone marrow, whilst leading to in enhanced lung injury and impaired inflammation resolution. We therefore propose that, the systemic hypoxia that defines severe lung 15 injury and ARDS, is not merely a marker of disease severity, but a key orchestrator shaping the immune responses in these conditions. Furthermore, hypoxic-driven inhibition of type I IFN may partly explain the association of hypoxia with poorer outcomes in viral-induced ALI, such as severe COVID-19 disease 47 There are no disease-modifying therapies available for ARDS, and in severe COVID-19 disease, most therapies are aimed at dampening the pro-inflammatory responses in the host. By using CSF1 as a therapy we propose to alter the immune responses at their origin, enhancing the pro-resolution capacity of the monocytes released in the blood stream. The therapeutic expansion of monocyte-derived macrophages in the lung may 5 appear to be counterintuitive given data in which the presence of 'activated' monocytes are associated with poor outcomes following coinfections 43 . Moreover, proinflammatory monocytes have been also linked to the cytokine storm observed in patients with severe COVID-19 disease 48 . The finding that CSF1-Fc, not only increases the number of monocytes and IM in the lung, but also alters their phenotype, helps explain this 10 discrepancy. At a transcriptional level, CSF1 treatment broadly restored the signature of circulating monocytes from hypoxia challenged mice to that observed in a normoxic state. It also upregulated 60% of the genes that were suppressed in the human ARDS monocyte populations. These phenotypic differences occurred in the CSF1-Fc-treated group despite the IM developing in a highly inflamed and hypoxic environment. This is 15 particularly interesting given that macrophages demonstrate great plasticity and the niche they inhabit is key to their functional imprinting, as reviewed recently 49 . In our system, CSF1 treatment led to a vast increase in IL-10 + IM with a concomitant increase in systemic IL-10. Macrophages are known to release IL-10 upon efferocytosis, 20 driving resolution of inflammation 34 . Furthermore, IL-10-producing IM have recently been shown to be key regulators of both allergic 9 and endotoxin-mediated lung injury 11 . CSF1 treatment also led to an increase in the number of Lyve1 + IM, a marker associated with a subgroup of macrophages that have been shown to be key to tissue repair in various disease contexts 50, 51 , including in the lung 12 . These findings strengthen the case of the therapeutic potential of manipulating the CSF1 axis in human ARDS. However, if CSF1, or indeed any MPS cell therapy, is to be considered as a therapeutic in ARDS, ensuring that the cells induced, or delivered, retain their pro-repair phenotype within the highly 5 inflamed niche they find themselves in, is fundamental. Further work in this area is therefore warranted. Taken together, our findings demonstrate the importance of hypoxia as an active participant in defining the immune landscape, and therefore outcomes, in acute lung injury. These findings, compounded with the effect of CSF1-Fc on accelerating 10 inflammation resolution and reducing lung injury, underscores the therapeutic potential of CSF1 as a novel treatment in ARDS. We are grateful to Prof D Hume for providing the CSF1-Fc used in these experiments. 15 We are grateful to Thomson Bioinformatics, 27 Strathalmond Road, Edinburgh, United Kingdom, for analysing the NanoString data. Flow cytometry data were generated with support from the QMRI Flow Cytometry and Cell Sorting Facility, University of Edinburgh. We are grateful to the Royal Infirmary of Edinburgh Critical Care Research Team for their assistance in recruiting, consenting and obtaining samples from patients with ARDS. This Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ananda Mirchandani 5 (Ananda.Mirchandani@ed.ac.uk) This study did not generate new unique reagents. Analyses, including the drawing of heatmaps and volcano plots were carried out in R 10 using the package ggplot2 (https://cran.r-project.org/web/packages/ggplot2/index.html). Analysis of datasets was carried out by Thomson Bioinformatics, Edinburgh, UK. 15 Patients with ARDS were recruited and informed consent obtained directly or by proxy Up to 20-40mls of whole blood was collected into citrate tubes and up to 10 million cells were stained for flow cytometry assessment and sorting. Briefly, the whole blood was treated with red cell lysis buffer (Invitrogen) and cells counted prior to staining for flow cytometry. Cells were incubated with anti-CD16/32 Fc-block (2:50) for 30 minutes followed by staining for 30 minutes with antibodies (see Table 1 ) followed by a wash with 5 FACS buffer (PBS+2% Fetal calf serum (FCS)). Dapi (1:1000) was added prior to flow cytometry to determine live cells. Monocytes were identified as Singles Dapi -CD45 + nongranulocyte Lin(CD3/CD56/CD19+/-CD66b) -HLADR + CD14 + and/or CD16 + cells. Samples obtained from April 2020 were fixed prior to acquisition given the potential for SARS-Cov2 dissemination. Briefly, 1uL of zombie Aqua fixable viability dye (stock 1:20 10 dilution) was added to 100uL of whole blood for 15 minutes at room temperature in the dark. 2uL of FcBlock was added for a further 30 minutes, on ice. Samples were then stained as above and fixed/ lysed using BD FACS Lyse for 10 minutes at room temperature. The sample was then resuspended in 300uL of FACS buffer and 50uL of Countbright beads added (Thermofisher) prior to acquisition. Male C57/BL6 mice aged 8-15 weeks were purchased from Envigo or Charles River. Ifnar -/-(ifnar tm/agt ) mice were obtained from J.S. who purchased them originally from the Jackson laboratory. Animal experiments were conducted in accordance with the UK Home Office Animals 20 (Scientific Procedures) Act of 1986 with local ethical approval. Mice were treated with nebulized LPS (3mg), and were then housed in normoxia or hypoxia (10% O2) for up to 5 days. Mice were treated with Colony Stimulating Factor (CSF)-1-Fc (kind gift from Prof D Hume) by subcutaneous injection (0.75g/g/mouse) from day 1 to 4 post-LPS, prior to cull on day 5. Mice were anesthetized and 10 7 colony forming units (or vehicle) were delivered in 50uL PBS via intratracheal intubation. Following reversal of anesthetic and a period of recovery, mice remained in normoxia, or were placed in hypoxia. Sickness scores were determined using methods as described previously 37 . 15 Mice were culled with an overdose of intraperitoneal anesthetic (Euthetal) followed by blood collection from the inferior vena cava. Alveolar leukocytes were collected by bronchoalveolar lavage (BAL), then mice were perfused lightly with PBS through the heart, prior to harvest of lung tissue. On occasion, lower limbs were harvested for bone marrow leukocyte assessment (see below). Mouse blood and bone marrow were treated with red blood cell lysis buffer (Biolegend) prior to counting and staining for flow cytometry (see Table 1 ). 10 Hematopoietic cell assessment was performed using both hind legs that were crushed using a pestle and mortar until a homogenous cell suspension was achieved or flushed though using a 32G needle. Cells were collected in cold FACS buffer and filtered through a 70 um nylon strainer (BD Falcon, 352340). Cells were treated with RBC lysis buffer (Biolegend) prior to staining 15 Tissue protected chimeras 6-8-week old C57BL/6J CD45.1 + CD45.2 + mice were anesthetized and were irradiated with a single dose of 9.5 Gy γ-irradiation while all but the hind legs and lower abdomen were protected by a 2 inch lead shield. The following day, the mice received 2-5 × 10 6 BM cells from CD45.2 + C57BL/6J by iv injection. Mouse Further gating strategy information can be made available upon request. 5 BAL and serum supernatants were collected and stored at -80°C until use. Cytokine and chemokine levels were measured using an MSD V-plex plate as per manufacturer's instructions. IgM BAL levels were measured using Ab133047 Abcam kit as per manufacturer's 10 instructions. BAL LDH activity (measured as colorimetric reduction of NAD to NADH) was performed using Ab102526 (Abcam) as per manufacturer's instructions. BAL total protein was measured using Pierce BCA Assay (Thermofisher) as per manufacturer's instructions 15 Naïve wild-type C57BL/6 bone marrow was obtained flushing the femoral and tibial bones and RBC were lysed. Cell were cultured in hypoxia (FiO2 1%) or normoxia (FiO2 21%) with conditioned DMEM for 1 hour prior to addition of IFNb 10ng/ml (RnD 8234-MB-010) for a further 3 hours. Cell pellets were collected and Qiagen RLT buffer added (containing 20 10uL/ml ß-mercaptoethanol). Pellets were snap frozen and stored at -80 for RNA extraction. RNA was isolated from bone marrow cells using the gDNA eliminator solution for purification of total RNA (RNeasy Plus Mini Kit, Qiagen). cDNA was synthesized by using AMV reverse transcriptase with random primers (Promega). TaqMan gene expression assays (Applied Biosystems, Thermo Fisher) and PrimeTime qPCR Probe Assays (IDT) were used for relative quantification of cDNA using SDS 2.4 (Thermo Fisher) and 5 normalized to ACTB expression. Murine paraffin-embedded blocks were prepared from lungs fixed via the trachea with 10% buffered formalin. The lung sections were stained with anti-IL10 (ab189392, Abcam), anti-F4/80 (ab6640, Abcam) or isotype control after deparaffinization and antigen 10 retrieval. The following were used TSA plus system amplification (NEL744B001KT, Perkin Elmer) and autofluorescence quenching with TrueView (Vector, SP-8400). The nuclei were stained with DAPI (422801, Sigma-Aldrich). Images were obtained using inverted Di8 microscope (Carl Zeiss). nCounter NanoString platform analysis 15 For human monocytes 5000 cells were sorted using the aforementioned human monocyte gating strategy directly into 2ul RLT buffer using a BD Fusion Sorter. 5000 mouse classical monocytes were sorted from mice treated with LPS and housed in normoxia, hypoxia and hypoxia+CSF1 gating on single DAPI -CD45 + Lin -CD115 + Ly6C hi cells into 2ul RLT. Cell pellets were vortexed and centrifuged prior to immediate freezing until ready Sorted monocytes were processed for proteomics using the 'in cell digest", as described Following digestion, and in order to generate the reference spectral library, peptides were subjected to reverse phase high pH tip fractionation following the general guidelines as described by Rappsilber et al 53 . In brief, tips for fractionation were made using three SDB-XC disks (Merck, UK) per tip. The tip was cleaned and conditioned using sequentially 15 methanol, 80% acetonitrile (MeCN) (Thermo Fisher Scientific, UK) in 0.1% NH4OH (v/v) and 0.1% NH4OH (52mM) (v/v). Peptides, resuspended also 0.1% NH4OH (pH=10), were spun through the SDB-XC disks and the flow-through was collected, acidified and concentrated on C-18 stage-Tips before subjected to MS analysis. Fractionation was then achieved by sequential elution with 7%, 14%, 21%, 28%, 35%, 55%, and 80% MeCN in Normalization of data was carried out using the geNorm selection of housekeeping genes function on NanoString nCounter analysis software. Resulting Log2 normalized values were used in subsequent analyses. Differential genes ("DE genes) were defined as genes with log2 FC>1, P-value <0.05 across sample groups. Hierarchical clustering of sets of 5 DE genes was carried out using Euclidian and Ward methods based on Pearson correlation values across transcriptional scores. Z-score scalar normalization of data was applied to the data prior to plotting as heatmaps. Analyses, including the drawing of heatmaps and volcano plots were carried out in R using the package ggplot2 (https://cran.r-project.org/web/packages/ggplot2/index.html). Analysis of datasets was 10 carried out by Thomson Bioinformatics, Edinburgh, UK. MS raw data files were processed using Spectronaut v14.7.201007.47784 using a human reference FASTA sequence from UniProt using default search parameters. The resulting protein-level data were analysed using R v3.5.0. Protein parts-per-million (ppm) 15 intensities were calculated by dividing the abundance of a protein by the total abundance measured in the sample and multiplied by a million. Fold-changes were calculated by dividing the mean ppm intensities between ARDS and healthy control samples. P-values were calculated using a t-test on log-transformed ppm intensities. Proteins were designated as significantly changing if they showed p-values < 0.05 and fold changes 20 exceeding 1.96 standard deviations away from the mean (i.e., z-score > 1.96). Only proteins that were quantitated in all samples are shown in the volcano plot. Statistical tests were performed using Prism 8.00 and 9.0.2 software (GraphPad Software Inc) (specific tests detailed in figure legends). Significance was defined as a p value of <0.05 (after correction for multiple comparisons where applicable). Sample sizes (with each n number representing a different blood donor for human cells or an individual mouse for animal experiments) are shown in figure legends. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome Cytokine balance in the lungs of patients with acute respiratory distress syndrome Self-renewal of pulmonary alveolar macrophages: evidence from radiation chimera studies The prolonged life-span of 20 alveolar macrophages Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes Lung interstitial macrophages alter dendritic cell functions to prevent 30 airway allergy in mice Exposure to Bacterial CpG DNA Protects from Airway Allergic Inflammation by Expanding Regulatory Lung Interstitial Macrophages The angiocrine Rspondin3 instructs interstitial macrophage transition via metabolic-epigenetic reprogramming and resolves inflammatory injury Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches The fate and lifespan of human monocyte subsets in steady state and systemic inflammation Critical but divergent roles 5 for CD62L and CD44 in directing blood monocyte trafficking in vivo during inflammation CD99 plays a major role in the migration of monocytes through endothelial junctions The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: attenuation of proinflammatory cytokine biosynthesis via feedback control of p38 Lipopolysaccharideinduced activation of NF-kappaB non-canonical pathway requires BCL10 serine 138 and NIK phosphorylations Dynamic change of chromatin conformation in response to hypoxia enhances the expression of GLUT3 (SLC2A3) by cooperative interaction of hypoxiainducible factor 1 and KDM3A CREB Negatively Regulates IGF2R Gene Expression and Downstream Pathways to Inhibit Hypoxia-Induced H9c2 Cardiomyoblast Cell Death Hypoxia-induced shift in the phenotype of proteasome from 26S 30 toward immunoproteasome triggers loss of immunoprivilege of mesenchymal stem cells Ferritin L and H subunits are differentially regulated on a post-transcriptional level Determination of the Oxyhaemoglobin Dissociation Curves for Mouse and Rat Blood Diverse macrophage populations mediate acute lung inflammation and resolution Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time Resident and pro-inflammatory macrophages in the colon represent 5 alternative context-dependent fates of the same Ly6Chi monocyte precursors Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy Longitudinal analyses reveal immunological misfiring in severe COVID-19 Type I interferons drive 15 inflammasome-independent emergency monocytopoiesis during endotoxemia Recombinant interferon-alpha for treatment of polycythaemia vera Lethal anemia caused by interferon-beta produced in mouse embryos carrying undigested DNA Characterisation of a novel Fc conjugate of macrophage colonystimulating factor Long-lived self-renewing bone marrow-derived macrophages displace embryo-derived cells to inhabit adult serous cavities Annexin A1: Uncovering the Many Talents of an Old Protein Regulatory T Cells Promote Macrophage Efferocytosis during Inflammation Resolution Phenotypic characterization of alveolar monocyte recruitment in acute respiratory distress syndrome Neutrophils and acute lung injury Hypoxia determines survival outcomes of bacterial infection through HIF-1alpha dependent re-programming of leukocyte metabolism Ly6C(+) monocyte efferocytosis and cross-presentation of cell-5 associated antigens Phagocyte partnership during the onset and resolution of inflammation Erythroid adaptation to altitude Effects of altitude acclimatization on blood composition of women Association Between Hypoxemia and Mortality in Patients With COVID-19 Comparative genomics of the lactic acid bacteria Granulocyte-Monocyte Progenitors and Monocyte-Dendritic Cell Progenitors Independently Produce Functionally Distinct Monocytes Progression of whole-blood transcriptional signatures from interferoninduced to neutrophil-associated patterns in severe influenza Type I interferon signaling regulates Ly6C(hi) monocytes and neutrophils 30 during acute viral pneumonia in mice Hypoxia in COVID-19: Sign of Severity or Cause for Poor Outcomes Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 Establishment and Maintenance of the Macrophage Niche Hyaluronan Receptor LYVE-1-Expressing Macrophages Maintain Arterial Tone through Hyaluronan-Mediated Regulation of Smooth Muscle Cell Collagen Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis Cell cycle state proteomics and classification using 5 in-cell protease digests and mass spectrometry. bioRxiv Protocol for micro-purification, enrichment, prefractionation and storage of peptides for proteomics using StageTips Higher-energy C-trap dissociation for peptide modification analysis 3 0 155 20 430 3 0 155 20 450 3 0 155 20 470 3 0 155 20 490 3 0 155 20 510 3 0 155 20 530 3 0 155 20 550 3 0 155 20 570 3 0 155 20 590 3 0 155 20 610 3 0 155 20 630 3 0 155 20 650 3 0 155 20 670 3 0 155 20 690 3 0 155 20 710 3 0 155 20 730 3 0 155 20 750 3 0 155 20 770 3 0 155 20 790 3 0 155 20 820 3 0 155 40 860 3 0 155 40 910 3 0 155 60 970 3 0 155 60